223 related articles for article (PubMed ID: 38084761)
1. Enzyme replacement therapy for late-onset Pompe disease.
Dalmia S; Sharma R; Ramaswami U; Hughes D; Jahnke N; Cole D; Smith S; Remmington T
Cochrane Database Syst Rev; 2023 Dec; 12(12):CD012993. PubMed ID: 38084761
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial.
Schoser B; Roberts M; Byrne BJ; Sitaraman S; Jiang H; Laforêt P; Toscano A; Castelli J; Díaz-Manera J; Goldman M; van der Ploeg AT; Bratkovic D; Kuchipudi S; Mozaffar T; Kishnani PS;
Lancet Neurol; 2021 Dec; 20(12):1027-1037. PubMed ID: 34800400
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial.
Diaz-Manera J; Kishnani PS; Kushlaf H; Ladha S; Mozaffar T; Straub V; Toscano A; van der Ploeg AT; Berger KI; Clemens PR; Chien YH; Day JW; Illarioshkin S; Roberts M; Attarian S; Borges JL; Bouhour F; Choi YC; Erdem-Ozdamar S; Goker-Alpan O; Kostera-Pruszczyk A; Haack KA; Hug C; Huynh-Ba O; Johnson J; Thibault N; Zhou T; Dimachkie MM; Schoser B;
Lancet Neurol; 2021 Dec; 20(12):1012-1026. PubMed ID: 34800399
[TBL] [Abstract][Full Text] [Related]
4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
5. Enzyme replacement therapy for infantile-onset Pompe disease.
Chen M; Zhang L; Quan S
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011539. PubMed ID: 29155436
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks: A Phase 3 Randomized Clinical Trial.
Kishnani PS; Diaz-Manera J; Toscano A; Clemens PR; Ladha S; Berger KI; Kushlaf H; Straub V; Carvalho G; Mozaffar T; Roberts M; Attarian S; Chien YH; Choi YC; Day JW; Erdem-Ozdamar S; Illarioshkin S; Goker-Alpan O; Kostera-Pruszczyk A; van der Ploeg AT; An Haack K; Huynh-Ba O; Tammireddy S; Thibault N; Zhou T; Dimachkie MM; Schoser B;
JAMA Neurol; 2023 Jun; 80(6):558-567. PubMed ID: 37036722
[TBL] [Abstract][Full Text] [Related]
7. Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease.
Dimachkie MM; Barohn RJ; Byrne B; Goker-Alpan O; Kishnani PS; Ladha S; Laforêt P; Mengel KE; Peña LDM; Sacconi S; Straub V; Trivedi J; Van Damme P; van der Ploeg AT; Vissing J; Young P; Haack KA; Foster M; Gilbert JM; Miossec P; Vitse O; Zhou T; Schoser B;
Neurology; 2022 Aug; 99(5):e536-e548. PubMed ID: 35618441
[TBL] [Abstract][Full Text] [Related]
8. Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis.
Dawson S; Girling CJ; Cowap L; Clark-Carter D
Cochrane Database Syst Rev; 2023 Mar; 3(3):CD013766. PubMed ID: 36989170
[TBL] [Abstract][Full Text] [Related]
9. Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study.
Pena LDM; Barohn RJ; Byrne BJ; Desnuelle C; Goker-Alpan O; Ladha S; Laforêt P; Mengel KE; Pestronk A; Pouget J; Schoser B; Straub V; Trivedi J; Van Damme P; Vissing J; Young P; Kacena K; Shafi R; Thurberg BL; Culm-Merdek K; van der Ploeg AT;
Neuromuscul Disord; 2019 Mar; 29(3):167-186. PubMed ID: 30770310
[TBL] [Abstract][Full Text] [Related]
10. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy.
Bus SR; de Haan RJ; Vermeulen M; van Schaik IN; Eftimov F
Cochrane Database Syst Rev; 2024 Feb; 2(2):CD001797. PubMed ID: 38353301
[TBL] [Abstract][Full Text] [Related]
11. Real-world outcomes from a series of patients with late onset Pompe disease who switched from alglucosidase alfa to avalglucosidase alfa.
Carter C; Boggs T; Case LE; Kishnani P
Front Genet; 2024; 15():1309146. PubMed ID: 38313679
[No Abstract] [Full Text] [Related]
12. Complementary and alternative therapies for post-caesarean pain.
Zimpel SA; Torloni MR; Porfírio GJ; Flumignan RL; da Silva EM
Cochrane Database Syst Rev; 2020 Sep; 9(9):CD011216. PubMed ID: 32871021
[TBL] [Abstract][Full Text] [Related]
13. Non-steroidal anti-inflammatory drugs for acute gout.
van Durme CM; Wechalekar MD; Landewé RB; Pardo Pardo J; Cyril S; van der Heijde D; Buchbinder R
Cochrane Database Syst Rev; 2021 Dec; 12(12):CD010120. PubMed ID: 34882311
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological treatment for familial amyloid polyneuropathy.
Magrinelli F; Fabrizi GM; Santoro L; Manganelli F; Zanette G; Cavallaro T; Tamburin S
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD012395. PubMed ID: 32311072
[TBL] [Abstract][Full Text] [Related]
15. Macrolide antibiotics (including azithromycin) for cystic fibrosis.
Southern KW; Solis-Moya A; Kurz D; Smith S
Cochrane Database Syst Rev; 2024 Feb; 2(2):CD002203. PubMed ID: 38411248
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological agents for adults with acute respiratory distress syndrome.
Lewis SR; Pritchard MW; Thomas CM; Smith AF
Cochrane Database Syst Rev; 2019 Jul; 7(7):CD004477. PubMed ID: 31334568
[TBL] [Abstract][Full Text] [Related]
17. Arthroscopic surgery for degenerative knee disease (osteoarthritis including degenerative meniscal tears).
O'Connor D; Johnston RV; Brignardello-Petersen R; Poolman RW; Cyril S; Vandvik PO; Buchbinder R
Cochrane Database Syst Rev; 2022 Mar; 3(3):CD014328. PubMed ID: 35238404
[TBL] [Abstract][Full Text] [Related]
18. Acupuncture and related interventions for the treatment of symptoms associated with carpal tunnel syndrome.
Choi GH; Wieland LS; Lee H; Sim H; Lee MS; Shin BC
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD011215. PubMed ID: 30521680
[TBL] [Abstract][Full Text] [Related]
19. Effect of avalglucosidase alfa on disease-specific and general patient-reported outcomes in treatment-naïve adults with late-onset Pompe disease compared with alglucosidase alfa: Meaningful change analyses from the Phase 3 COMET trial.
Toscano A; Pollissard L; Msihid J; van der Beek N; Kishnani PS; Dimachkie MM; Berger KI; DasMahapatra P; Thibault N; Hamed A; Zhou T; Haack KA; Schoser B
Mol Genet Metab; 2024 Feb; 141(2):108121. PubMed ID: 38184428
[TBL] [Abstract][Full Text] [Related]
20. Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis.
Smith S; Rowbotham NJ
Cochrane Database Syst Rev; 2022 Nov; 11(11):CD001021. PubMed ID: 36373968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
